SAN FRANCISCO — Fledgling high-content screening company Cellumen has landed its first customer as part of its hybrid business strategy to be an HCS service provider as well as a reagent provider, Inside Bioassays has learned.

In an interview conducted at Cambridge Healthtech Institute’s High-Content Analysis conference held here two weeks ago, Lansing Taylor, Cellumen’s CEO, said that Cellumen has forged a partnership with an undisclosed biotech that will serve as a litmus test for its proposed dual business strategy.